Join our community of smart investors

Oxford/AstraZeneca trial paused due to illness

Standard review process has led the company to put studies on hold
September 9, 2020

A late-stage trial for a potential Covid-19 vaccine being developed by Oxford University and AstraZeneca (AZN) has been paused, due to a possible serious adverse reaction in a participant. Health publication Stat News, which first reported the update on Tuesday evening, said that the participant in question was based in the UK and is expected to recover.

IC TIP: Buy at 8222p
This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in